A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort

Table 2 Mean urinary (±SD) concentrations of ten biomarkers assessed by ELISA in cohort of 288 subjects

Biomarker	Total bladder cancer	Low-grade bladder cancer	High-grade bladder cancer	NMIBC	MIBC	Controls
	(75.9 %)	(41.2 %)	(58.8 %)	(80.6 %)	(19.4 %)	(24.1 %)
	n = 211	n = 87	n = 124	n = 170	n = 41	n = 67
IL8 (pg/mL)^abc	1.224 ± 1.387	0.763 ± 0.824	1.547 ± 1.598	1.020 ± 1.177	2.070 ± 1.826	0.566 ± 0.464
MMP9 (ng/mL)^abc	0.485 ± 0.536	0.311 ± 0.261	0.607 ± 0.638	0.411 ± 0.434	0.792 ± 0.770	0.319 ± 0.366
SERPINA1 (ng/mL)^abc	2.648 ± 2.538	1.891 ± 1.594	3.180 ± 2.920	2.312 ± 2.147	4.041 ± 3.444	1.061 ± 0.711
ANG (pg/mL)^abc	2.133 ± 1.181	1.812 ± 0.928	2.358 ± 1.286	1.979 ± 1.037	2.770 ± 1.504	1.190 ± 0.543
VEGF (pg/mL)^abc	1.852 ± 1.021	1.570 ± 0.610	2.050 ± 1.193	1.731 ± 0.897	2.352 ± 1.322	1.386 ± 0.395
CA9 (pg/mL)^abc	0.770 ± 0.971	0.577 ± 0.480	0.905 ± 1.185	0.668 ± 0.805	1.190 ± 1.411	0.357 ± 0.242
MMP10 (pg/mL)^abc	0.989 ± 1.625	0.626 ± 0.422	1.243 ± 2.055	0.814 ± 1.346	1.713 ± 2.353	0.517 ± 0.492
APOE (pg/mL)^abc	0.639 ± 0.427	0.491 ± 0.307	0.744 ± 0.468	0.571 ± 0.373	0.923 ± 0.518	0.420 ± 0.177
SERPINE1 (ng/mL)^abc	0.156 ± 0.181	0.096 ± 0.080	0.198 ± 0.217	0.125 ± 0.134	0.284 ± 0.273	0.056 ± 0.030
SDC1 (pg/mL)^a	0.489 ± 0.140	0.468 ± 0.127	0.504 ± 0.147	0.478 ± 0.129	0.534 ± 0.172	0.331 ± 0.121

NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer
^a P < 0.05 comparing total bladder cancer to total controls
^b P < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer
^c P < 0.05 comparing NMIBC to MIBC

ISSN: 1479-5876